160 related articles for article (PubMed ID: 36731341)
1. SGLT2 inhibitor ertugliflozin decreases elevated intracellular sodium, and improves energetics and contractile function in diabetic cardiomyopathy.
Croteau D; Baka T; Young S; He H; Chambers JM; Qin F; Panagia M; Pimentel DR; Balschi JA; Colucci WS; Luptak I
Biomed Pharmacother; 2023 Apr; 160():114310. PubMed ID: 36731341
[TBL] [Abstract][Full Text] [Related]
2. Effects of Sodium-Glucose Linked Transporter 2 Inhibition With Ertugliflozin on Mitochondrial Function, Energetics, and Metabolic Gene Expression in the Presence and Absence of Diabetes Mellitus in Mice.
Croteau D; Luptak I; Chambers JM; Hobai I; Panagia M; Pimentel DR; Siwik DA; Qin F; Colucci WS
J Am Heart Assoc; 2021 Jul; 10(13):e019995. PubMed ID: 34169737
[TBL] [Abstract][Full Text] [Related]
3. Decreased ATP production and myocardial contractile reserve in metabolic heart disease.
Luptak I; Sverdlov AL; Panagia M; Qin F; Pimentel DR; Croteau D; Siwik DA; Ingwall JS; Bachschmid MM; Balschi JA; Colucci WS
J Mol Cell Cardiol; 2018 Mar; 116():106-114. PubMed ID: 29409987
[TBL] [Abstract][Full Text] [Related]
4. Energetic Dysfunction Is Mediated by Mitochondrial Reactive Oxygen Species and Precedes Structural Remodeling in Metabolic Heart Disease.
Luptak I; Qin F; Sverdlov AL; Pimentel DR; Panagia M; Croteau D; Siwik DA; Bachschmid MM; He H; Balschi JA; Colucci WS
Antioxid Redox Signal; 2019 Sep; 31(7):539-549. PubMed ID: 31088291
[No Abstract] [Full Text] [Related]
5. Increasing mitochondrial ATP synthesis with butyrate normalizes ADP and contractile function in metabolic heart disease.
Panagia M; He H; Baka T; Pimentel DR; Croteau D; Bachschmid MM; Balschi JA; Colucci WS; Luptak I
NMR Biomed; 2020 May; 33(5):e4258. PubMed ID: 32066202
[TBL] [Abstract][Full Text] [Related]
6. Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study.
Gaborit B; Ancel P; Abdullah AE; Maurice F; Abdesselam I; Calen A; Soghomonian A; Houssays M; Varlet I; Eisinger M; Lasbleiz A; Peiretti F; Bornet CE; Lefur Y; Pini L; Rapacchi S; Bernard M; Resseguier N; Darmon P; Kober F; Dutour A
Cardiovasc Diabetol; 2021 Mar; 20(1):57. PubMed ID: 33648515
[TBL] [Abstract][Full Text] [Related]
7. Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy.
Arow M; Waldman M; Yadin D; Nudelman V; Shainberg A; Abraham NG; Freimark D; Kornowski R; Aravot D; Hochhauser E; Arad M
Cardiovasc Diabetol; 2020 Jan; 19(1):7. PubMed ID: 31924211
[TBL] [Abstract][Full Text] [Related]
8. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na
Uthman L; Baartscheer A; Bleijlevens B; Schumacher CA; Fiolet JWT; Koeman A; Jancev M; Hollmann MW; Weber NC; Coronel R; Zuurbier CJ
Diabetologia; 2018 Mar; 61(3):722-726. PubMed ID: 29197997
[TBL] [Abstract][Full Text] [Related]
9. SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob
Adingupu DD; Göpel SO; Grönros J; Behrendt M; Sotak M; Miliotis T; Dahlqvist U; Gan LM; Jönsson-Rylander AC
Cardiovasc Diabetol; 2019 Feb; 18(1):16. PubMed ID: 30732594
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Na+-H+ exchanger protects diabetic and non-diabetic hearts from ischemic injury: insight into altered susceptibility of diabetic hearts to ischemic injury.
Ramasamy R; Schaefer S
J Mol Cell Cardiol; 1999 Apr; 31(4):785-97. PubMed ID: 10329206
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of the cardiac Na+/Ca2+ exchanger increases susceptibility to ischemia/reperfusion injury in male, but not female, transgenic mice.
Cross HR; Lu L; Steenbergen C; Philipson KD; Murphy E
Circ Res; 1998 Dec 14-28; 83(12):1215-23. PubMed ID: 9851938
[TBL] [Abstract][Full Text] [Related]
12. New Na(+)-H+ exchange inhibitor HOE 694 improves postischemic function and high-energy phosphate resynthesis and reduces Ca2+ overload in isolated perfused rabbit heart.
Hendrikx M; Mubagwa K; Verdonck F; Overloop K; Van Hecke P; Vanstapel F; Van Lommel A; Verbeken E; Lauweryns J; Flameng W
Circulation; 1994 Jun; 89(6):2787-98. PubMed ID: 8205693
[TBL] [Abstract][Full Text] [Related]
13. The sodium-glucose co-transporter-2 inhibitor ertugliflozin modifies the signature of cardiac substrate metabolism and reduces cardiac mTOR signalling, endoplasmic reticulum stress and apoptosis.
Moellmann J; Mann PA; Kappel BA; Kahles F; Klinkhammer BM; Boor P; Kramann R; Ghesquiere B; Lebherz C; Marx N; Lehrke M
Diabetes Obes Metab; 2022 Nov; 24(11):2263-2272. PubMed ID: 35801343
[TBL] [Abstract][Full Text] [Related]
14. Empagliflozin attenuates arrhythmogenesis in diabetic cardiomyopathy by normalizing intracellular Ca
Kadosaka T; Watanabe M; Natsui H; Koizumi T; Nakao M; Koya T; Hagiwara H; Kamada R; Temma T; Karube F; Fujiyama F; Anzai T
Am J Physiol Heart Circ Physiol; 2023 Mar; 324(3):H341-H354. PubMed ID: 36607794
[TBL] [Abstract][Full Text] [Related]
15. Energy metabolism, intracellular Na+ and contractile function in isolated pig and rat hearts during cardioplegic ischemia and reperfusion: 23Na- and 31P-NMR studies.
Kupriyanov VV; Xiang B; Butler KW; St-Jean M; Deslauriers R
Basic Res Cardiol; 1995; 90(3):220-33. PubMed ID: 7575375
[TBL] [Abstract][Full Text] [Related]
16. Off-target effects of sodium-glucose co-transporter 2 blockers: empagliflozin does not inhibit Na+/H+ exchanger-1 or lower [Na+]i in the heart.
Chung YJ; Park KC; Tokar S; Eykyn TR; Fuller W; Pavlovic D; Swietach P; Shattock MJ
Cardiovasc Res; 2021 Dec; 117(14):2794-2806. PubMed ID: 33135077
[TBL] [Abstract][Full Text] [Related]
17. Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium.
Cappetta D; De Angelis A; Ciuffreda LP; Coppini R; Cozzolino A; Miccichè A; Dell'Aversana C; D'Amario D; Cianflone E; Scavone C; Santini L; Palandri C; Naviglio S; Crea F; Rota M; Altucci L; Rossi F; Capuano A; Urbanek K; Berrino L
Pharmacol Res; 2020 Jul; 157():104781. PubMed ID: 32360273
[TBL] [Abstract][Full Text] [Related]
18. Functional resilience of C57BL/6J mouse heart to dietary fat overload.
Tadinada SM; Weatherford ET; Collins GV; Bhardwaj G; Cochran J; Kutschke W; Zimmerman K; Bosko A; O'Neill BT; Weiss RM; Abel ED
Am J Physiol Heart Circ Physiol; 2021 Nov; 321(5):H850-H864. PubMed ID: 34477461
[TBL] [Abstract][Full Text] [Related]
19. Novel Small-Molecule Troponin Activator Increases Cardiac Contractile Function Without Negative Impact on Energetics.
He H; Baka T; Balschi J; Motani AS; Nguyen KK; Liu Q; Slater R; Rock B; Wang C; Hale C; Karamanlidis G; Hartman JJ; Malik FI; Reagan JD; Luptak I
Circ Heart Fail; 2022 Mar; 15(3):e009195. PubMed ID: 34743528
[TBL] [Abstract][Full Text] [Related]
20. BH4 Increases nNOS Activity and Preserves Left Ventricular Function in Diabetes.
Carnicer R; Duglan D; Ziberna K; Recalde A; Reilly S; Simon JN; Mafrici S; Arya R; Roselló-Lletí E; Chuaiphichai S; Tyler D; Lygate CA; Channon KM; Casadei B
Circ Res; 2021 Mar; 128(5):585-601. PubMed ID: 33494625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
